The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
650
Zenagamtide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Relative change in body weight
Measured as percentage (%) change in body weight.
Time frame: From week 0 to week 84
Change in waist circumference
Measured as centimetre (cm).
Time frame: From week 0 to week 84
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo matched to zenagamtide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
First Valley Medical Group
Lancaster, California, United States
Desert Oasis Healthcare
Palm Springs, California, United States
Western University of Health Sciences
Pomona, California, United States
Artemis Insitute for Clin Res
San Diego, California, United States
Med Home Development Grp
Washington D.C., District of Columbia, United States
Encore Medical Research LLC
Hollywood, Florida, United States
NextPhase Research
Hollywood, Florida, United States
Jacksonville Ctr Clin Res
Jacksonville, Florida, United States
PharmaDev Clinical Research Institute LLC
Miami, Florida, United States
South Broward Research LLC
Miramar, Florida, United States
...and 33 more locations